⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KLRS News
Kalaris Therapeutics, Inc. Common Stock
Kalaris to Present at Clinical Trials at the Summit 2026
globenewswire.com
KLRS
Form 8-K
sec.gov
KLRS
Kaskela Law LLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. Shareholders and Encourages Investors With Losses to Contact The Firm - KLRS
accessnewswire.com
KLRS
Form 8-K
sec.gov
KLRS
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
KLRS
Form 8-K
sec.gov
KLRS
Form 8-K
sec.gov
KLRS
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
globenewswire.com
KLRS
Form 8-K
sec.gov
KLRS
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
globenewswire.com
KLRS